Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27651649 | 0.87 | LIPE (0.50) | LIPEKMT2ARAB9APOLBAKR1C3 | |
| SCHEMBL12834636 | 0.86 | LIPE (0.65) | LIPEMEN1KMT2APOLBKDM4E | |
| SCHEMBL7550336 | 0.80 | LIPE (1.00) | LIPEMEN1KMT2A | |
| SCHEMBL4663484 | 0.80 | LIPE (0.74) | LIPEMEN1KMT2A | |
| SCHEMBL10757188 | 0.80 | LIPE (0.73) | LIPEMEN1KMT2ARAB9AKDM4E | |
| SCHEMBL1115881 | 0.79 | CYP1A2 (0.64) | MEN1KMT2ARAB9APOLBAKR1C3 | |
| SCHEMBL11831902 | 0.79 | MEN1 (0.65) | MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL5067764 | 0.79 | LMNA (0.59) | MEN1KMT2A | |
| SCHEMBL2918462 | 0.79 | MAPT (0.69) | MEN1KMT2ARAB9AAKR1C3KDM4E | |
| SCHEMBL31596882 | 0.78 | LIPE (0.58) | LIPEMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298292-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298292-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298291-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298291-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| US-20050090471-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC (US) | 2005-04-28 | — | — | US | disclosed |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004092139-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004089342-A2 | ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXIPIENT | ALTANA PHARMA AG (DE) | 2004-10-21 | — | — | WO | disclosed |
| EP-1446405-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC Biotech Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6753329-B2 | 1,5-DIHYDROPYRAZOLO(3,4-D)PYRIMIDIN-4-ONE DERIVATIVES USEFUL FOR TRATING CANCER, TUMOR AND HYPERPROLIFERATIVE DISORDERS IN ANIMALS | GPC BIOTECH INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030162797-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH AG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003033499-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | LIPE 4213/4885MEN1 3326/4885KMT2A 937/4885 |
| US-20030162797-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | LIPE 4213/4885MEN1 3326/4885KMT2A 937/4885 |
| US-20050090471-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | LIPE 4213/4885MEN1 3326/4885KMT2A 937/4885 |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | LIPE 4213/4885MEN1 3326/4885KMT2A 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.